Compare ARK Genomic Revolution ETF (ARKG) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs HCA Health Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while HCA Health Inc trades at $404.6 (market cap $90.20B). The key difference: HCA Health Inc pays a 0.77% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | HCA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $545.13 |
52-Week Low | $23.09 | $334.32 |
Market Cap | — | $90.20B |
Enterprise Value | — | $139.10B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
HCA Healthcare trades at $406.59, down 0.59% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $7.37. Revenue growth is robust, reaching $75.60 billion in 2025, while valuation metrics like a P/E of 14.01 and EV/EBITDA of 8.88 suggest relative attractiveness. Recent news highlights capacity expansion and gene therapy advancements.
The outlook for HCA remains positive, supported by earnings momentum and strategic investments, but risks include high debt levels and regulatory pressures. Analyst consensus is bullish with a $486.10 price target, indicating ~20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
